Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28545889 | 1.00 | BCHE (0.31) | BCHEALDH1A1 | |
| SCHEMBL31267130 | 0.82 | BCHE (0.39) | BCHEALDH1A1 | |
| SCHEMBL22262566 | 0.81 | JAK2 (0.35) | BCHEALDH1A1 | |
| SCHEMBL26382257 | 0.79 | BCHE (0.41) | BCHEALDH1A1 | |
| SCHEMBL17616927 | 0.78 | ALDH1A1 (0.42) | BCHEALDH1A1 | |
| SCHEMBL22627598 | 0.78 | ALDH1A1 (0.42) | BCHEALDH1A1 | |
| SCHEMBL17252155 | 0.78 | ALDH1A1 (0.42) | BCHEALDH1A1 | |
| SCHEMBL20613593 | 0.78 | ALDH1A1 (0.42) | BCHEALDH1A1 | |
| SCHEMBL17252165 | 0.78 | ALDH1A1 (0.42) | BCHEALDH1A1 | |
| SCHEMBL14423339 | 0.78 | ALDH1A1 (0.42) | BCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| CN-112574236-B | RET inhibitor, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | BCHE 4767/4885ALDH1A1 641/4885 |
| US-20200239494-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | BCHE 4767/4885ALDH1A1 641/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | BCHE 4767/4885ALDH1A1 641/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | BCHE 4767/4885ALDH1A1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.